^
Association details:
| Biomarker: | LTBP1_E2-ALK_E11 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib
Excerpt:
...a 58‐year old man treated with crizotinib as first‐line treatment after 2.6 month…The tumor specimen harbored EML4_E13:ALK_E19 fusion and the matched blood plasma was detected with a novel LTBP1_E2:ALK_E11 fusion variant with EML4_E13:ALK_E19 and concomitant L1196M mutation at disease progression.
DOI:
10.1111/1759-7714.13071
